

In the claims:

Please amend the claims as follows:

Claim 1. (Previously Amended) A method for the treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an anti-alpha4 integrin antibody homolog or antigen binding fragment thereof.

①³ Claim 2. (Currently Amended) The method of claim 1, wherein the ~~antagonist~~ antibody homolog is an alpha 4/beta 1 (VLA4) ~~antibody homolog integrin-binding agent~~.

Claim 3 (Withdrawn)

Claim 4. (Previously Amended) The method of claim 1, wherein the anti-alpha 4 integrin antibody homolog is selected from the group consisting of a) an antibody homolog that antagonizes the interaction of both VLA-4 and alpha4 beta 7 with their respective alpha4 ligands; b) an antibody homolog that antagonizes the interaction of VLA-4 with its alpha4 ligand; and c) an antibody homolog that antagonizes the interaction of alpha4beta7 with its alpha4 ligand.

Claim 5. (Currently Amended) The method of claim 4, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, and a humanized antibody ~~and fragments thereof~~.

Claims 6-8 (Withdrawn)

Claim 9. (Previously Amended) The method of claim 1, wherein the composition is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg body weight of the antibody homolog or antigen binding fragment thereof.

Claims 10-29 (Withdrawn)

Claim 30. (New) The method of claim 1, wherein the antibody homolog is an alpha 4/beta 7 antibody homolog.

Claim 31. (New) The method of claim 1, wherein the antibody homolog is a human or humanized antibody.

Claim 32. (New) The method of claim 2, wherein the antibody homolog is a human or humanized antibody.

Claim 33. (New) The method of claim 30, wherein the antibody homolog is a human or humanized antibody.

3
Claim 34. (New) The method of claim 2, wherein the VLA-4 antibody homolog is an HP1/2 antibody homolog.

Claim 35. (New) The method of claim 2, wherein the VLA-4 antibody homolog is an HP2/1 antibody homolog.

Claim 36. (New) The method of claim 2, wherein the VLA-4 antibody homolog is an HP2/4 antibody homolog.

Claim 37. (New) The method of claim 2, wherein the VLA-4 antibody homolog is an L25 antibody homolog.

Claim 38. (New) The method of claim 2, wherein the VLA-4 antibody homolog is a P4C2 antibody homolog.

Claims 39. (New) The method of claim 2, wherein the VLA-4 antibody homolog is a P4G9 antibody homolog.

Claims 40. (New) The method of claim 2, wherein the VLA-4 antibody homolog is a humanized anti-VLA-4 antibody comprising a humanized light chain and a humanized heavy chain, the light chain and the heavy chain each comprising complementarity determining regions (CDR1, CDR2 and CDR3) from murine 21-6 anti-VLA-4 antibody.

23
Claim 41. (New) The method of claim 40, wherein (a) the humanized light chain comprises a variable region framework from a human kappa light chain variable region framework sequence, wherein at least one amino acid position of the framework region is occupied by the amino acid present in the equivalent position of the mouse 21.6 immunoglobulin light chain variable region framework; and (b) the humanized heavy chain comprises a variable region framework from a human heavy chain variable region framework sequence, wherein at least one amino acid position of the framework region is occupied by the amino acid present in the equivalent position of the mouse 21-6 immunoglobulin heavy chain variable region framework.
